Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galcanezumab for episodic migraine prevention (China, Phase 3)
CTR20190735Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of galcanezumab in migraine, sponsored by Eli Lilly and Company. Started Jul 2019; status: completed.
02
Drugs
galcanezumab
03
Conditions
migraine
Beyond the preview
Go deeper on CTR20190735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190735.